Mentioned in ?
References in periodicals archive ?
1 million for the full-year 2009, as an 18% increase in revenue from Tysabri was partially offset by the expected lower revenue from Maxipime, Azactam and Prialt.
Elan ceased distributing Azactam as of March 31, 2010 and will not earn any future revenues from this product.
These increases were primarily driven by increased revenue from Tysabri, offset by the expected lower revenues from Azactam and Prialt.
The increase in revenues from the BioNeurology business was driven by Tysabri, which more than offset the expected reduced revenues from Azactam and Prialt.
6 million operating loss before other net charges recorded by the BioNeurology business in the second quarter of 2009, and reflects the continued growth in Tysabri revenues offsetting the expected reduced revenues from Azactam and Prialt, in addition to an 18% reduction in combined SG&A and R&D expenses.
For the full-year 2009, revenue from Azactam decreased 16% to $81.
Elan will cease distributing Azactam as of March 31, 2010.
The increase was primarily driven by strong growth in Tysabri sales, which more than compensated for reduced sales of Azactam and Maxipime.
The decreases for both of the comparative periods principally reflect reduced sales and marketing costs and amortization expense related to Maxipime and Azactam.
2 million relating to the Maxipime and Azactam intangible assets, arising from the approval of a first generic cefepime hydrochloride in June 2007 and an anticipated approval for a generic form of Azactam.
3 million in the same period of 2007, principally reflecting reduced sales and marketing costs and amortization expense relating to Maxipime and Azactam, and the operating leverage associated with Tysabri, and can be analyzed as follows:
6 million in the same period of 2007, principally reflecting reduced amortization costs associated with Maxipime and Azactam and can be analyzed as follows: